1 day Ago By Defense World Staff
Alkermes ( NASDAQ:ALKS – Get Free Report ) ‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $48.00 price target on the stock.
Cantor Fitzgerald’s price objective would indicate a potential upside of 73.04% from the stock’s previous close. Other analysts have also recently issued research reports about the company.
TD Cowen started coverage on Alkermes in a research report on Monday, June 17th. They set a “buy” rating and a $34.00 target price on the stock.
StockNews.com upgraded Alkermes from a “hold” rating to a “buy” rating in a research report on Sunday, July 28th. Robert W.
Baird boosted their price target on Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th.
HC Wainwright boosted their price target on Alkermes from $35.00 to $37.00 and gave the company a “neutral” rating in a research report on Thursday, July 25th.
Finally, JPMorgan Chase & Co. boosted their price target on Alkermes from $31.00 to $32.
00 and gave the company a “neutral” rating in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $36.
70. Read Our Latest Analysis on Alkermes Alkermes Stock Down 0.3 % Alkermes ( NASDAQ:ALKS – Get Free Report ) last announced its quarterly earnings results on Wednesday, July 24th.
The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70.
Alkermes had a return on equity of 23.20% and a net margin of 19.15%.
The company had revenue of $399.13 million during the quarter, compared to the consensus estimate of $393.30 million.
During the same period in the previous year, the business earned $0.38 EPS. Alkermes’s revenue for the quarter was down 35.
4% on a year-over-year basis. On average, analysts forecast that Alkermes will post 2.36 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Alkermes Several large investors have recently modified their holdings of ALKS. Dimensional Fund Advisors LP lifted its position in shares of Alkermes by 3.9% during the fourth quarter.
Dimensional Fund Advisors LP now owns 2,403,195 shares of the company’s stock worth $66,666,000 after purchasing an additional 90,219 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Alkermes by 1,150.
2% in the fourth quarter. Principal Financial Group Inc. now owns 939,542 shares of the company’s stock worth $26,063,000 after acquiring an additional 864,389 shares during the last quarter.
Vanguard Personalized Indexing Management LLC lifted its holdings in Alkermes by 25.7% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 9,845 shares of the company’s stock worth $273,000 after acquiring an additional 2,015 shares during the last quarter.
Janney Montgomery Scott LLC bought a new position in Alkermes in the fourth quarter worth about $927,000. Finally, Norges Bank bought a new position in Alkermes in the fourth quarter worth about $55,548,000. Institutional investors own 95.
21% of the company’s stock. Alkermes Company Profile ( Get Free Report ) Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Recommended Stories Five stocks we like better than Alkermes Airline Stocks – Top Airline Stocks to Buy Now Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? How to Evaluate a Stock Before Buying Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge 3 REITs to Buy and Hold for the Long Term Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter ..
